Ehrich Elliot
EVP, R&D & CMO, Alkermes, Inc. at ALKS; SVP, R&D & Chief Medical Ofcr at ALKERMES INC
- Sold, on record
- $30.5M
- Dollars the filings state
- Form 4 sales
- 61
- Latest Apr 17, 2017
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- ALKSAlkermes plc.EVP, R&D & CMO, Alkermes, Inc.
- ALKERMES INCSVP, R&D & Chief Medical Ofcr
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- ALKS784,574 shares
- ALKERMES INC101,964 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale ALKSPlan not statedSep 22 2016
Sold 5,000 shares at $50.83 ($254k)
Ehrich Elliot, EVP, R&D & CMO, Alkermes, Inc.
Sold 9.9% of holdings ($2.6M position)45,311 shares left0.3x usual sizeFiling
- 2 Form 4 sale ALKSPlan not statedDec 12 +81 days
Sold 16,983 shares at $55.15 ($937k)
Ehrich Elliot, EVP, R&D & CMO, Alkermes, Inc.
Sold 24.4% of holdings ($3.8M position)52,640 shares left0.9x usual sizeFiling
- 3 Form 4 sale ALKSPlan not statedDec 15 +3 days
Sold 5,000 shares at $55.99 ($280k)
Ehrich Elliot, EVP, R&D & CMO, Alkermes, Inc.
Sold 8.7% of holdings ($3.2M position)52,640 shares left0.3x usual sizeFiling
- 4 Form 4 sale ALKSPlan not statedJan 6 +22 days
Sold 10,000 shares at $59.45 ($594k)
Ehrich Elliot, EVP, R&D & CMO, Alkermes, Inc.
Sold 16% of holdings ($3.7M position)52,640 shares left0.6x usual sizeFiling
- 5 Form 4 sale ALKSPlan not statedJan 17 +11 days
Sold 11,983 shares at $54.32 ($651k)
Ehrich Elliot, EVP, R&D & CMO, Alkermes, Inc.
Sold 19.1% of holdings ($3.4M position)50,657 shares left1x usual sizeFiling
- 6 Form 4 sale ALKSPlan not statedFeb 16 +30 days
Sold 11,000 shares at $56.68 ($623k)
Ehrich Elliot, EVP, R&D & CMO, Alkermes, Inc.
Sold 18.1% of holdings ($3.4M position)49,657 shares left0.9x usual sizeFiling
- 7 Form 4 sale ALKSPlan not statedMar 15 +27 days
Sold 11,000 shares at $56.74 ($624k)
Ehrich Elliot, EVP, R&D & CMO, Alkermes, Inc.
Sold 16.6% of holdings ($3.7M position)55,071 shares left1x usual sizeFiling
- 8 Form 4 sale ALKSPlan not statedApr 17 +33 days
Sold 10,000 shares at $56.60 ($566k)
Ehrich Elliot, EVP, R&D & CMO, Alkermes, Inc.
Sold 15.4% of holdings ($3.7M position)55,071 shares left0.9x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (61)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Apr 17, 2017 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 10,000 | $566k | 15.4% | Plan not stated | SEC |
| Mar 15, 2017 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 11,000 | $624k | 16.6% | Plan not stated | SEC |
| Feb 16, 2017 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 11,000 | $623k | 18.1% | Plan not stated | SEC |
| Jan 17, 2017 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 11,983 | $651k | 19.1% | Plan not stated | SEC |
| Jan 6, 2017 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 10,000 | $594k | 16.0% | Plan not stated | SEC |
| Dec 15, 2016 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 5,000 | $280k | 8.7% | Plan not stated | SEC |
| Dec 12, 2016 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 16,983 | $937k | 24.4% | Plan not stated | SEC |
| Sep 22, 2016 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 5,000 | $254k | 9.9% | Plan not stated | SEC |
| Sep 16, 2016 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 5,000 | $244k | 9.9% | Plan not stated | SEC |
| Sep 6, 2016 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 10,000 | $460k | 18.1% | Plan not stated | SEC |
| Jul 27, 2016 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 35,199 | $1.8M | 43.7% | Unusual | SEC |
| Apr 13, 2016 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 11,698 | $441k | 22.2% | Plan not stated | SEC |
| Apr 21, 2015 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 25,000 | $1.6M | 50.0% | Unusual | SEC |
| Mar 16, 2015 | ALKS | EVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 18,000 | $1.2M | 41.9% | Unusual | SEC |
| Feb 17, 2015 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 18,000 | $1.3M | 43.9% | Unusual | SEC |
| Jan 15, 2015 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 18,375 | $1.2M | 44.4% | Unusual | SEC |
| Aug 11, 2014 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 16,667 | $694k | 42.0% | Unusual | SEC |
| Jul 9, 2014 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 16,667 | $790k | 42.0% | Unusual | SEC |
| Jun 19, 2014 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 17,282 | $814k | 42.9% | Unusual | SEC |
| Jun 9, 2014 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 16,667 | $803k | 42.0% | Unusual | SEC |
| May 22, 2014 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 2,378 | $106k | 10.2% | Plan not stated | SEC |
| May 21, 2014 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 1,981 | $87k | 8.6% | Plan not stated | SEC |
| May 19, 2014 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 2,206 | $96k | 9.5% | Plan not stated | SEC |
| Feb 18, 2014 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 7,718 | $405k | 31.8% | Unusual | SEC |
| Jan 21, 2014 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 7,718 | $375k | 31.8% | Unusual | SEC |
| Jan 16, 2014 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 14,555 | $689k | 46.7% | Unusual | SEC |
| Dec 18, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 60,854 | $2.4M | 78.6% | Unusual | SEC |
| Nov 19, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 10,357 | $390k | 38.5% | Unusual | SEC |
| Oct 18, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 7,718 | $273k | 31.8% | Unusual | SEC |
| Sep 18, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 7,722 | $269k | 31.8% | Unusual | SEC |
| Jun 3, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 36,864 | $1.1M | 69.0% | Unusual | SEC |
| May 28, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 1,122 | $38k | 6.3% | Plan not stated | SEC |
| May 22, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 2,375 | $77k | 12.5% | Plan not stated | SEC |
| May 21, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 4,184 | $130k | 20.2% | Plan not stated | SEC |
| Mar 8, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 30,000 | $676k | 64.4% | Unusual | SEC |
| Jan 31, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 6,500 | $150k | 28.2% | Unusual | SEC |
| Jan 17, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 100,048 | $2.2M | 85.8% | Unusual | SEC |
| Jan 9, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 7,000 | $154k | 20.1% | Plan not stated | SEC |
| Jan 7, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 7,000 | $147k | 20.1% | Plan not stated | SEC |
| Jan 4, 2013 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 71,500 | $1.4M | 71.9% | Unusual | SEC |
| Dec 21, 2012 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 28,134 | $549k | 50.2% | Unusual | SEC |
| Dec 12, 2012 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 1,866 | $36k | 6.3% | Plan not stated | SEC |
| Dec 11, 2012 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 27,000 | $513k | 49.2% | Unusual | SEC |
| Dec 7, 2012 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 44,500 | $834k | 61.5% | Unusual | SEC |
| Nov 21, 2011 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 3,412 | $50k | 15.9% | Plan not stated | SEC |
| Nov 8, 2011 | ALKS | SVP, R&D & CMO, Alkermes, Inc. | Form 4 sale | 341 | $5k | 1.9% | Plan not stated | SEC |
| Jun 2, 2011 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 1,023 | $18k | 5.2% | Plan not stated | SEC |
| May 31, 2011 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 1,023 | $19k | 4.8% | Plan not stated | SEC |
| May 27, 2011 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 1,450 | $26k | 6.3% | Plan not stated | SEC |
| May 18, 2011 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 2,849 | $51k | 11.7% | Plan not stated | SEC |
| May 12, 2011 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 5,000 | $85k | 18.8% | Plan not stated | SEC |
| Nov 19, 2010 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 3,412 | $37k | 11.4% | Plan not stated | SEC |
| Nov 8, 2010 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 341 | $4k | 1.3% | Plan not stated | SEC |
| Sep 17, 2010 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 35,000 | $525k | 56.4% | Unusual | SEC |
| Sep 13, 2010 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 5,000 | $70k | 13.5% | Plan not stated | SEC |
| Jun 25, 2010 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 15,245 | $198k | 29.1% | Unusual | SEC |
| Jun 23, 2010 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 3,496 | $43k | 8.6% | Plan not stated | SEC |
| Jan 26, 2010 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 15,244 | $186k | 27.6% | Unusual | SEC |
| Nov 6, 2009 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 341 | $3k | 0.8% | Plan not stated | SEC |
| Jun 29, 2009 | ALKERMES INC | SVP, R&D & Chief Medical Ofcr | Form 4 sale | 7,724 | $83k | 15.5% | Plan not stated | SEC |
| Sep 12, 2007 | ALKERMES INC | VP, Science and Development | Form 4 sale | 4,816 | $80k | 14.2% | Plan not stated | SEC |